Sabra Health Care REIT, Inc.
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
SBRA$21.32-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $40,813 | $40,304 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 53,131 | 43,494 |
| Non-cash rental and related revenues | (1,599) | (2,428) |
| Non-cash interest income | — | 4 |
| Non-cash interest expense | 2,368 | 1,729 |
| Stock-based compensation expense | 3,098 | 2,711 |
| Recovery of loan losses | (213) | (173) |
| Impairment of real estate | 440 | — |
| Income from unconsolidated joint ventures | (1,912) | (218) |
| Distributions of earnings from unconsolidated joint ventures | 1,657 | 2,368 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, prepaid expenses and other assets, net | (1,534) | (2,822) |
| Accounts payable and accrued liabilities | 2,113 | (4,706) |
| Net cash provided by operating activities | 98,362 | 80,263 |
| Cash flows from investing activities: | ||
| Acquisition of real estate and lease intangibles | (96,101) | (7,854) |
| Origination and fundings of loans receivable | — | (1,710) |
| Origination and fundings of preferred equity investments | (15) | (9) |
| Additions to real estate | (11,851) | (7,783) |
| Escrow deposits for potential investments | (430) | — |
| Repayments of loans receivable | 1,944 | 1,129 |
| Repayments of preferred equity investments | 1,256 | 813 |
| Investment in unconsolidated joint ventures | — | (1,030) |
| Insurance proceeds | 107 | — |
| Net cash used in investing activities | (105,090) | (16,444) |
| Cash flows from financing activities: | ||
| Net borrowings from (repayments of) revolving credit facility | 137,800 | (23,881) |
| Principal payments on secured debt | (531) | (517) |
| Payments of deferred financing costs | (92) | (80) |
| Contributions from noncontrolling interests | 4 | — |
| Payment of contingent consideration | (1,178) | — |
| Issuance of common stock, net | (8,247) | (5,391) |
| Dividends paid on common stock | (75,657) | (71,373) |
| Net cash provided by (used in) financing activities | 52,099 | (101,242) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 45,371 | (37,423) |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash | (60) | (19) |
| Cash, cash equivalents and restricted cash, beginning of period | 78,140 | 66,339 |
| Cash, cash equivalents and restricted cash, end of period | $123,451 | $28,897 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $15,071 | $20,233 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.